title: Evaluation of the in vitro skin permeation of antiviral drugs from penciclovir 1% cream and acyclovir 5% cream used to treat herpes simplex virus infection.
abstract: BACKGROUND
  Herpes simplex virus infection (HSV) is a common and ubiquitous infection of the skin which causes mucocutaneous lesions called cold sores (herpes labialis) or fever blisters. It is estimated that approximately 80% of the population worldwide are carriers of the Herpes simplex virus, approximately 40% suffer from recurrent recurrent infections. This study evaluates the in vitro skin permeation and penetration of penciclovir and acyclovir from commercialized creams for the treatment of herpes labialis (cold sores), using non viable excised human abdominal skin samples, which were exposed to 5 mg/cm2 of acyclovir 5% cream or penciclovir 1% cream.
  
  
  METHODS
  After 24 h of cream application, excess cream was washed off and layers of stratum corneum were removed by successive tape stripping. Amounts of active ingredients having penetrated through the skin were measured, as well as the amounts in the washed-off cream, in skin strips and creams remaining in the skin. Molecular modelling was used to evaluate physico-chemical differences between the drugs. Western blot analysis enabled to determine whether the marker of basal cells keratin 5 could be detected in the various tape strips.
  
  
  RESULTS
  Application of penciclovir 1% cream yielded higher concentration of drug in the deeper layers of the epidermis as well as a higher drug flux through the skin. Molecular modelling showed two higher hydrophobic moieties for acyclovir. Presence of the basal cell marker keratin 5 was underscored in the deeper tape strips from the skin, giving evidence that both drugs can reach their target cells.
  
  
  CONCLUSIONS
  Penciclovir 1% cream has the tendency to facilitate the diffusion of the drug through the stratum corneum into the deeper epidermis layers, in which it could reach the target basal cells at effective therapeutical concentration. The small difference in the surface properties between both molecules might also contribute to favour the passage of penciclovir through the epidermis into the deeper basal cells.
authors.affiliation: Department of Preclinical Development, Novartis Consumer Health, Nyon, Switzerland. nathalie.hasler-nguyen@novartis.com
authors.forename: Nathalie
authors.initials: N
authors.lastname: Hasler-Nguyen
authors.forename: Donald
authors.initials: D
authors.lastname: Shelton
authors.forename: Gilbert
authors.initials: G
authors.lastname: Ponard
authors.forename: Marlene
authors.initials: M
authors.lastname: Bader
authors.forename: Martina
authors.initials: M
authors.lastname: Schaffrik
authors.forename: Pascal
authors.initials: P
authors.lastname: Mallefet